Anti-prolactin autoantibodies in pregnant women with systemic lupus erythematosus: Maternal and fetal outcome

Lupus

Volumn 16, Issue 5, 2007, Pages 342-349

  Leaños Miranda, Alfredo ^a,c   Cardenas Mondragon G ^a   Ulloa Aguirre, A ^a   Isordia Salas, I ^a   Parra, A ^b   Ramirez Peredo J ^b  

^a Hospital Luis Castelazo Ayala   (Mexico)

^b INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^c Research Unit in Reproductive Medicine   (Mexico)

Author keywords

Anti prolactin autoantibodies; Lupus pregnancy; Prolactin

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; PROLACTIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; CONTROLLED STUDY; FEMALE; FETUS OUTCOME; GEL FILTRATION CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL WELFARE; PREGNANT WOMAN; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; THIRD TRIMESTER PREGNANCY;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; AUTOANTIBODIES; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, GEL; FEMALE; FETUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOTHERS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROLACTIN; STILLBIRTH;

EID: 34447538193     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307078197     Document Type: Article

References (43)

1. Gimovsky ML, Montoro M, Paul RH. Pregnancy outcome in women with systemic lupus erythematosus. Obstet Gynecol 1984; 63: 686-692.
2. Mintz G, Niz J, Gutiérrez C. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J Rheumatol 1986; 13: 732-739.
3. Out HJ, Derksen RH, Christiaens GC. Systemic lupus erythematosus and pregnancy. Obstet Gynecol Surv 1989; 44: 585-591.
4. Petri M, Allbritton J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. J Rheumatol 1993; 20: 650-656.
5. Ruiz-Irastorza G, Lima F, Alves J et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheum 1996; 35: 133-138.
6. Petri M. Hopkins lupus pregnancy center 1987 to 1996. Rheum Dis Clin North Am 1997; 23: 195-212.
7. Khamashta MA, Ruiz-Irastorza GR, Hughes GRV. Systemic lupus erythematosus flares during pregnancy. Rheum Dis Clin North Am 1997; 23: 15-30.
8. Georgiou PE, Politi EN, Katsimbri P et al. Outcome of lupus pregnancy: a controlled study. Rheumatology 2000; 39: 1014-1019.
9. Yasmeen S, Wilkins EE, Field NT et al. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001; 10: 91-96.
10. Kiss E, Bhattoa HP, Bettembuk P et al. Pregnancy in women with systemic lupus erythematosus. Eur J Obstet Gynecol Reprod Biol 2002; 101: 129-134.
11. Cortés-Henrández J, Ordi-Ros J, Paredes F et al. Clinical predictors of fetal and maternal outcome in systemic lupus erytheamrosus: a prospective study of 103 pregnancies. Rheumatology 2002; 41: 643-650.
12. Blanco-Favela F, Quintal-Alvarez G, Leaños-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999; 26: 55-59.
13. Pacilio M, Migliaresi S, Meli R et al. Elevated bioactive prolactin in systemic lupus erythematosus=association with disease activity. J Rheumatol 2001; 28: 2216-2221.
14. Jacobi AM, Rhode W, Ventz M et al. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001; 10: 554-561.
15. McMurray R, Keisler D, Kanuekel K et al. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991; 147: 780-787.
16. Fraser IS, Lung ZG. Polymers of prolactin and their clinical significance. Obstet Gynecol Surv 1990; 45: 515-520.
17. Hattori N. The frequency of macroprolactinemia in pregnant women and heterogeneity of its etiologies. J Clin Endocrinol Metab 1996; 81: 586-590.
18. Pascoe-Lira D, Duran-Reyes G, Contreras-Hernández I et al. Frequency of macroprolactinemia due to autoantibodies against prolactin in pregnant women. J Clin Endocrinol Metab 2001; 86: 924-929.
19. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1989; 16: 354-364.
20. Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J Clin Endocrinol Metab 1981; 53: 863-866.
21. Andersen AN, Pedersen H, Djursin H et al. Bioactivity of prolactin in a woman with an excess of large molecular size prolactin, persistent hyperprolactinemia and spontaneous conception. Fertil Steril 1982; 38: 625-628.
22. Jackson RD, Wortsman J, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 1985; 61: 258-264.
23. De Schepper J, Schiettecatte J, Velkeniers B et al. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endcorinol 2003; 149: 201-207.
24. Amadori P, Dilberis C, Marcolla A et al. Identification of IgG-immunocomplex macroprolactin with an immunometric 'sandwich' system: technical and clinical considerations. J Endocrinol Invest 2004; 27: 1022-1028.
25. Leaños A, Pascoe D, Fraga A et al. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus 1998; 7: 398-403.
26. Leaños-Miranda A, Chávez-Rueda KA, Blanco-Favela F. Biologic activity and clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 866-875.
27. Leaños-Miranda A, Pascoe-Lira D, Chávez-Rueda KA et al. Persistence of macroprolactinemia due to antiprolactin autoantibody before, during, and after pregnancy in a woman with systemic lupus erythematosus. J Clin Endocrinol Metab 2001; 86: 2619-2624.
28. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1272-1277.
29. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
30. Bombardier C, Gladman D, Urowitz M et al. The Committee on Prognosis Studies in SLE: derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
31. Leaños-Miranda A, Pascoe-Lira D, Blanco-Favela F. Prolactin and systemic lupus erythematosus (Letter). Br J Rheumatol 1998; 37: 1029-1030.
32. Leaños-Miranda A, Pascoe-Lira D, Chávez-Rueda KA et al. Anti-prolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. J Rheumatol 2001; 28: 1546-1553.
33. Leaños-Miranda A, Pascoe-Lira D, Chávez-Rueda KA et al. Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia. Lupus 2001; 10: 340-345.
34. Leaños-Miranda A, Contreras-Hernández I. Anti-prolactin autoantibodies are associated with hyperprolactinemic status in men infected with human immunodeficiency virus. Endocrine 2002; 19: 139-146.
35. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102: 181-192.
36. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for the definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
37. Muñoz-Valle JF, Vázquez-Del Mercado M, García- Iglesias T et al. Th1/Th2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 2003; 131: 377-384.
38. Lynch A, Marlar R, Murphy J et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994; 120: 470-476.
39. Bole-Feysot C, Goffin V, Edery M et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-268.
40. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002; 57: 435-455.
41. Peeva E, Michael D, James C et al. Prolactin modulates the naive B cell repertoire. J Clin Invest 2003; 111: 275-283.
42. Glezer A, Soares CR, Vieira JG et al. Human macroprolactin display low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 2006; 91: 1048-1055.
43. Leaños-Miranda A, Cárdenas-Mondragón G, Rivera-Leaños Roxana et al. Application of new homologous in vitro bioassays for human lactogens to asses the actual bioactivity of human prolactin isoforms in hyperprolactinemic patients. Clin Endocrinol 2006; 65: 146-153.